About 100 reports

  • METABOLIC DISORDERS DRUGS

Drugs For Respiratory Diseases P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A

  • Endocrine Disease
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • CLINICAL NUTRITION MARKET: REVENUE IN USD MILLION, BY DISEASE TYPE, GLOBAL, 2018-2023
  • 7.3 BY END USER

GASTROINTESTINAL DISORDER IS ONE OF THE MOST COMMON DISORDERS IN THE AGED POPULATION, WHO REQUIRE CLINICAL NUTRITION AS SUPPLEMENT TO MAINTAIN THE BODY-ENERGY BALANCE.

  • Endocrine Disease
  • World
  • Market Size
  • Baxter International Inc.
  • Fresenius Group
  • Key market highlights

Approximately one in three adults with diabetes and one in five adults with high blood pressure has chronic kidney diseases.

  • Endocrine Disease
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • Galenica Group
  • Causes of Iron Deficiency Anemia (IDV)

Inflammatory Bowl Diseases (IBD), which causes gastrointestinal bleeding leads to iron deficiency, is one major disorder under gastroenterology requiring I. V.

  • Endocrine Disease
  • World
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • ASTRAZENECA PLC

It is involved in discovering, developing, manufacturing, and commercializing prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases globally.

  • Endocrine Disease
  • World
  • AstraZeneca PLC
  • Horizon Pharma plc
  • Novo Nordisk Group

Top ## players hold majority of stake in the market ##.

  • Endocrine Disease
  • World
  • Market Size
  • Baxter International Inc.
  • Gilead Sciences, Inc.

GLP-## IS AN INCRETIN HORMONE THAT IS RELEASED FROM CELLS IN THE GASTROINTESTINAL TRACT INTO THE CIRCULATION IN RESPONSE TO INGESTED NUTRIENTS FROM FOOD.

  • Endocrine Disease
  • Southeast Asia
  • Market Size
  • Novo Nordisk Group
  • Sanofi S.A.

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Endocrine Disease
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • ESTIMATE OF BARIATRIC SURGERY NUMBERS IN THE US (2011−2015)
  • GLOBAL IV AND ORAL IRON DRUG MARKET IN ONCOLOGY 2015−2021 (US$ MILLION)

Also, the people in the age group ##−## years, ## in ## men and ## in ## women suffer from CKD across the world.

  • Endocrine Disease
  • World
  • Actavis plc
  • AMAG Pharmaceuticals, Inc.
  • Vifor Pharma

GASTROINTESTINAL ADVERSE EFFECTS WERE MORE COMMON IN THE VICTOZA TREATMENT ARM COMPARED TO BYDUREON.

  • Endocrine Disease
  • United States
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Takeda Pharmaceutical Company Limited
  • 2.2 A CONTINUED FOCUS ON IMPROVING THE COMPLIANCE AND SAFETY OF PHOSPHATE BINDER DRUGS

PLOS ONE; ##(##): ##-##.

  • Endocrine Disease
  • Amgen Inc.
  • AstraZeneca PLC
  • Keryx Biopharmaceuticals, Inc.
  • OPKO Health, Inc.

GLP-## is an incretin hormone that is released from cells in the gastrointestinal tract into the circulation in response to ingested nutrients from food.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

CURRENT OPINION IN ONCOLOGY; ##(##): ##-##.

  • Endocrine Disease
  • Forecast
  • Amgen Inc.
  • Keryx Biopharmaceuticals, Inc.
  • OPKO Health, Inc.

It manifests as dysfunction of one or more organ systems including the cardiovascular, gastrointestinal, genitourinal, sudomotor and ocular systems.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.
  • PEPTIDE THERAPEUTICS IN METABOLIC DISORDERS: TECHNOLOGY PLATFORMS

THIS IS DONE TO DECREASE THE PROBABILITY OF GASTROINTESTINAL SYMPTOMS.

  • Endocrine Disease
  • Australia
  • United States
  • LipimetiX Development LLC
  • Novartis AG

GASTROINTESTINAL (GI) DISORDERS ##. ##. ##.

  • Endocrine Disease
  • United States
  • Enterome Bioscience SA
  • MicroBiome Therapeutics LLC
  • Seres Therapeutics, Inc.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • Research Contact: info@globaldata.com
  • 5.6.1 PHARMACEUTICALS & HEALTHCARE, GLOBAL, METABOLIC DISORDERS DEALS, 2016 BY QUARTER

Besides, one PE deal worth USD##m was recorded in Q## 2017.

  • Endocrine Disease
  • Neurology
  • World
  • Company
  • Deals & Alliance

Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Immunology and Undisclosed which include indications Obesity, Dyslipidemia, Hyperlipidemia, Inflammation, Non-Alcoholic Steatohepatitis (NASH), Type ## Diabetes and Unspecified.

  • Endocrine Disease
  • Therapy
  • United States
  • World
  • Product Initiative

Besides, one VC deal worth USD##. ##m was reported in Q## 2016.

  • Endocrine Disease
  • Pharmaceutical
  • World
  • Company
  • Deals & Alliance
  • Ipsen SA, Deals By Therapy Area, 2012 to YTD 2018
  • 02/13/2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

SR One Ltd.

  • Endocrine Disease
  • United States
  • Company Financials
  • Demand
  • Ipsen S.A.
  • Iron-deficiency Anemia Therapy Market: Revenue in USD million, Oral Iron Therapy, Global, 2015-2025
  • Iron-Deficiency Anemia Therapy Market: Revenue in USD million, United Kingdom, 2015-2025

In the United Kingdom, it affects one in three patients in the hospital, and one in ## women in the population.

  • Endocrine Disease
  • United States
  • World
  • Market Size
  • Keryx Biopharmaceuticals, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2017 (CONTD..1), H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2017

## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## PC ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Dis ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## P I ## ## ## ## ## ## ## ##

  • Blood Disease
  • Endocrine Disease
  • United States
  • Company
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H1 2018

Atherosclerosis - Overview Atherosclerosis - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR ATHEROSCLEROSIS, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR ATHEROSCLEROSIS, H## 2018 Phase III ## ## Phase II ## ## Phase I ## ## Preclinical ## ## Discovery ## ##

  • Digestive System Disorder
  • Endocrine Disease
  • United States
  • Product Initiative
  • Esperion Therapeutics, Inc.
  • Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H1 2018
  • Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H1 2018

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Endocrine Disease
  • Japan
  • United States
  • Product Initiative
  • Kyowa Hakko Kirin Co., Ltd.
  • Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H2 2018
  • Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2018

The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Endocrine Disease
  • Therapy
  • United States
  • Product Initiative
  • EA Pharma Co., Ltd.